Pharmaceuticals in U.S. health care: Determinants of quantity and price

Journal of Economic Perspectives

Volumn 16, Issue 4, 2002, Pages 45-66

  Berndt, Ernst R ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG COST; DRUG INDUSTRY; DRUG THERAPY; ECONOMICS; FEE; FORECASTING; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; PHARMACOECONOMICS; REVIEW; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

DRUG COSTS; DRUG INDUSTRY; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; FEES, PHARMACEUTICAL; FORECASTING; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; UNITED STATES;

EID: 0040077826     PISSN: 08953309     EISSN: None     Source Type: Journal    
DOI: 10.1257/089533002320950975     Document Type: Review

References (31)

1. Berndt, Ernst R. 2000. "International Comparisons of Pharmaceutical Prices: What Do We Know, and What Does it Mean?" Journal of Health Economics. March/April, 19:2, pp. 283-87.
2. Berndt, Ernst R. 2001. "The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?" Health Affairs. March/April, 20:2, pp. 100-14.
3. Berndt, Ernst R., Margaret K. Kyle and Davina Ling. 2002. "The Long Shadow of Patent Expiration: Generic Entry and Rx to OTC Switches," in Scanner Data and Price Indexes, NBER Series on the Conference on Research in Income and Wealth. Robert C. Feenstra and Matthew D. Shapiro, eds. Chicago: University of Chicago Press for the National Bureau of Economic Research, forthcoming.
4. Berndt, Ernst R. et al. 2000. "Comparing SSRI Treatment Costs for Depression Using Retrospective Claims Data: The Role of Nonrandom Selection and Skewed Data." Value in Health. May/June, 3:3, pp. 208-21.
5. Berndt, Ernst R. et al. 2002. "The Medical Treatment of Depression, 1991-1996: Productive Inefficiency, Expected Outcome Variations, and Price Indexes." Journal of Health Economics. May, 21:3, pp. 373-96.
6. Copeland, Craig. 2000. "Prescription Drugs: Continued Rapid Growth." Washington, D.C., Employee Benefit Research Institute Notes, September.
7. Danzon, Patricia M. 1997. "Price Discrimination for Pharmaceuticals: Welfare Effects in the U.S. and the E.U." International Journal of the Economics of Business. November, 4:3, pp. 301-21.
8. Danzon, Patricia M. and Li-Wei Chao. 2000. "Cross-National Price Differences for Pharmaceuticals: How Large, and Why?" Journal of Health Economics. March/April, 19:2, pp. 159-96.
9. Dorfman, Robert and Peter O. Steiner. 1954. "Optimal Advertising and Optimal Quality." American Economic Review. December, 44:5, pp. 826-36.
10. Ellison, Sara F. and Christopher M. Snyder. 2001. "Countervailing Power in Wholesale Pharmaceuticals." Working Paper 01-27, MIT Department of Economics, July.
11. Elzinga, Kenneth G. and David E. Mills. 1997. "The Distribution and Pricing of Drugs." International Journal of the Economics of Business. November, 4:3, pp. 287-99.
12. Frank, Richard G. 2001. "Prescription Drug Prices: Why Do Some Pay More Than Others Do?" Health Affairs. March/April, 20:2, pp. 115-28.
13. Grabowski, Henry and John Vernon. 1996. "Longer Patents for Increased Generic Competition in the U.S.: The Waxman-Hatch Act after One Decade." PharmacoEconomics. 10: Supplement 2, pp. 110-23.
14. Grabowski, Henry, John Vernon and Joseph DiMasi. 2002. "Returns on R&D for 1990s New Drug Introductions." Unpublished Working Paper, Duke University, Department of Economics, March.
15. Harris, Gardner. 2002. "Merck to Shed Medco, its Drug-Benefits Unit, in Bid to Boost Stock." New York Times. January 29, pp. A1, A8.
16. Hellerstein, Judith K. 1998. "The Importance of the Physician in the Generic versus Trade-Name Prescription Decision." RAND Journal of Economics. Spring, 29:1, pp. 108-36.
17. Iglehart, John K., ed. 2001. The Value of Rx Innovation: A Primer from Health Affairs. Millwood, Va.: Project HOPE.
18. IMS Health. 2002. "IMS Reports 16.9 Percent Growth in 2001 U.S. Prescription Sales." Available at 〈http://www.imshealth.com/public/ structure〉.
19. Kremer, Michael. 2000a. "Creating Markets for New Vaccines. Part I: Rationale." NBER Paper No. 7716.
20. Kremer, Michael. 2000b. "Creating Markets for New Vaccines. Part II: Design Issues." NBER Working Paper No. 7717.
21. Lu, Z. John and William S. Comanor. 1998. "Strategic Pricing of New Pharmaceuticals." Review of Economics and Statistics. February, 80:1, pp. 108-18.
22. Nelson, Philip. 1974. "Advertising as Information." Journal of Political Economy. July/August, 82:4, pp. 729-54.
23. Newhouse, Joseph P. and the Insurance Experiment Group. 1993. Free for All? Lessons from the RAND Health Insurance Experiment. Cambridge, Mass.: Harvard University Press.
24. Petitti, Diana B. 2002. "Hormone Replacement Therapy for Prevention. More Evidence, More Pessimism. "Journal of the American Medical Association. July 3, 288:1, pp. 99-101.
25. Rosenthal, Meredith B. et al. 2002a. "Promotion of Prescription Drugs to Consumers." New England Journal of Medicine. February 14, 346:7, pp. 498-505.
26. Rosenthal, Meredith B. et al. 2002b. "Demand Effects of Recent Changes in Prescription Drug Promotion," in Frontiers in Health Policy Research, Volume 5. Alan M. Garber, ed. Cambridge, Mass.: MIT Press for the National Bureau of Economic Research, forthcoming.
27. Scherer, F. Michael. 2001. "The Link Between Gross Profitability and Pharmaceutical R&D Spending." Health Affairs. September/October, 20:5, pp. 216-20.
28. Takeeda-Lilly Prescription Drug Benefit Cost and Plan Design Survey Report. 2001. Temple, Ariz.: Pharmacy Benefit Management Institute, Inc.
29. United States Congressional Budget Office. 1997. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Washington, D.C.: U.S. Government Printing Office.
30. United States Office of Technology Assessment. 1993. Pharmaceutical R&D: Costs, Risks and Rewards. Washington, D.C.: U.S. Government Printing Office.
31. Wennberg, John E., Elliott S. Fisher and Jonathan S. Skinner. 2002. "Geography and the Debate Over Medicare Reform." Health Affairs. Available online at 〈http://www.healthaffairs. org/WebExclusives/Wennberg_Web_Excl_ 021302.htm〉.